Experienced in Hypertrophic Cardiomyopathy (HCM)

Dr. Ron Waksman

Interventional Cardiology | Cardiology
Medstar Heart Institute LLC
110 Irving St Nw, 
Washington, DC 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Experienced in Hypertrophic Cardiomyopathy (HCM)
Medstar Heart Institute LLC
110 Irving St Nw, 
Washington, DC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ron Waksman is an Interventional Cardiologist and a Cardiologist in Washington, Washington, D.c.. Dr. Waksman is rated as an Experienced provider by MediFind in the treatment of Hypertrophic Cardiomyopathy (HCM). His top areas of expertise are Aortic Valve Stenosis, Coronary Heart Disease, Heart Attack, Transcatheter Aortic Valve Replacement (TAVR), and Aortic Valve Replacement. Dr. Waksman is currently accepting new patients.

His clinical research consists of co-authoring 935 peer reviewed articles and participating in 26 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Hypertrophic Cardiomyopathy (HCM).

Specialties
Interventional Cardiology
Cardiology
Licenses
Internal Medicine in DC
Hospital Affiliations
Medstar Washington Hospital Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

MEDSTAR HEART INSTITUTE LLC
110 Irving St Nw, Washington, DC 20010

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

26 Clinical Trials

Edwards PASCAL TrAnScatheter Valve RePair System Pivotal Clinical Trial (CLASP IID/IIF): A Prospective, Multicenter, Randomized, Controlled Pivotal Trial to Evaluate the Safety and Effectiveness of Transcatheter Mitral Valve Repair With the Edwards PASCAL Transcatheter Valve Repair System Compared to Abbott MitraClip in Patients With Mitral Regurgitation
Edwards PASCAL TrAnScatheter Valve RePair System Pivotal Clinical Trial (CLASP IID/IIF): A Prospective, Multicenter, Randomized, Controlled Pivotal Trial to Evaluate the Safety and Effectiveness of Transcatheter Mitral Valve Repair With the Edwards PASCAL Transcatheter Valve Repair System Compared to Abbott MitraClip in Patients With Mitral Regurgitation
Enrollment Status: Recruiting
Publish Date: May 21, 2025
Intervention Type: Device
Study Phase: Not Applicable
Evaluation of the Portico™ NG (Next Generation) Transcatheter Aortic Valve in High and Extreme Risk Patients With Symptomatic Severe Aortic Stenosis
Evaluation of the Portico™ NG (Next Generation) Transcatheter Aortic Valve in High and Extreme Risk Patients With Symptomatic Severe Aortic Stenosis
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2025
Intervention Type: Device
Study Phase: Not Applicable
Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial
Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial
Enrollment Status: Active_not_recruiting
Publish Date: July 20, 2025
Intervention Type: Device
Study Phase: Not Applicable
Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes Registry
Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes Registry
Enrollment Status: Active_not_recruiting
Publish Date: June 13, 2025
Outcomes of Percutaneous Revascularization for Management of Surgically Ineligible Patients With Multivessel or Left Main Coronary Artery Disease: A Prospective Registry
Outcomes of Percutaneous Revascularization for Management of Surgically Ineligible Patients With Multivessel or Left Main Coronary Artery Disease: A Prospective Registry
Enrollment Status: Active_not_recruiting
Publish Date: May 15, 2025
Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI)
Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI)
Enrollment Status: Active_not_recruiting
Publish Date: May 01, 2025
Intervention Type: Device, Procedure
Study Phase: Not Applicable
WATCHMAN for Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement
WATCHMAN for Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement
Enrollment Status: Completed
Publish Date: May 22, 2024
Intervention Type: Device
Study Phase: Not Applicable
Feasibility of Transcatheter Aortic Valve Replacement in Low-Risk Patients With Symptomatic, Severe Aortic Stenosis
Feasibility of Transcatheter Aortic Valve Replacement in Low-Risk Patients With Symptomatic, Severe Aortic Stenosis
Enrollment Status: Completed
Publish Date: May 16, 2024
Intervention Type: Device
Study Phase: Not Applicable
Annular ReduCtion for Transcatheter Treatment of Insufficient Mitral ValvE (ACTIVE): A Prospective, Multicenter, Randomized, Controlled Pivotal Trial to Assess Transcatheter Mitral Valve Repair With Edwards Cardioband System and GDMT vs GDMT Alone in Patients With FMR and Heart Failure
Annular ReduCtion for Transcatheter Treatment of Insufficient Mitral ValvE (ACTIVE): A Prospective, Multicenter, Randomized, Controlled Pivotal Trial to Assess Transcatheter Mitral Valve Repair With Edwards Cardioband System and GDMT vs GDMT Alone in Patients With FMR and Heart Failure
Enrollment Status: Terminated
Publish Date: November 30, 2023
Intervention Type: Drug, Device
Study Phase: Not Applicable
a Multinational, Multicenter, Prospective, Open-label, Active-treatment-controlled Randomized Trial: Preventive PCI or Medical Therapy Alone for Vulnerable Atherosclerotic Coronary Plaque_PREVENT Trial
a Multinational, Multicenter, Prospective, Open-label, Active-treatment-controlled Randomized Trial: Preventive PCI or Medical Therapy Alone for Vulnerable Atherosclerotic Coronary Plaque_PREVENT Trial
Enrollment Status: Completed
Publish Date: November 18, 2023
Intervention Type: Device, Drug
Study Drug: Optimal Medical treatment
Study Phase: Phase 4
A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions
A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions
Enrollment Status: Completed
Publish Date: October 30, 2023
Intervention Type: Device
Study Phase: Not Applicable
A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions.
A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions.
Enrollment Status: Completed
Publish Date: October 11, 2023
Intervention Type: Device
Study Phase: Not Applicable
Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial
Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial
Enrollment Status: Active_not_recruiting
Publish Date: October 06, 2023
Intervention Type: Device
Study Phase: Not Applicable
AltaValve Early Feasibility Study Protocol
AltaValve Early Feasibility Study Protocol
Enrollment Status: Unknown
Publish Date: September 01, 2023
Intervention Type: Device
Study Phase: Not Applicable
CoreValve Evolut Pro Prospective Registry
CoreValve Evolut Pro Prospective Registry
Enrollment Status: Unknown
Publish Date: May 26, 2023
Intervention Type: Device
Prospective, Multicenter, Single-Arm, Global IDE Study of the Shockwave Coronary Intravascular Lithotripsy (IVL) System With the Shockwave C2 Coronary IVL Catheter in Calcified Coronary Arteries
Prospective, Multicenter, Single-Arm, Global IDE Study of the Shockwave Coronary Intravascular Lithotripsy (IVL) System With the Shockwave C2 Coronary IVL Catheter in Calcified Coronary Arteries
Enrollment Status: Completed
Publish Date: May 19, 2023
Intervention Type: Device
Study Phase: Not Applicable
THE ALIGN-AR TRIAL: Safety and Effectiveness/Performance of the Transfemoral JenaValve Pericardial TAVR System in the Treatment of Patients With Symptomatic Severe Aortic Regurgitation (AR)
THE ALIGN-AR TRIAL: Safety and Effectiveness/Performance of the Transfemoral JenaValve Pericardial TAVR System in the Treatment of Patients With Symptomatic Severe Aortic Regurgitation (AR)
Enrollment Status: Active_not_recruiting
Publish Date: November 18, 2022
Intervention Type: Device
Study Phase: Not Applicable
A Study to Assess Safety and Effectiveness of the JenaValve Trilogy™ Heart Valve System in the Treatment of High Surgical Risk Patients With Symptomatic, Severe Aortic Regurgitation (AR)
A Study to Assess Safety and Effectiveness of the JenaValve Trilogy™ Heart Valve System in the Treatment of High Surgical Risk Patients With Symptomatic, Severe Aortic Regurgitation (AR)
Enrollment Status: Active_not_recruiting
Publish Date: September 13, 2022
Intervention Type: Device
Study Phase: Not Applicable
XIENCE 28 USA Study
XIENCE 28 USA Study
Enrollment Status: Completed
Publish Date: May 03, 2022
Intervention Type: Drug, Device
Study Phase: Not Applicable
RENAL ARTERY IRRADIATION FOR SYMPATHETIC RENAL DENERVATION IN PATIENTS WITH RESISTANT HYPERTENSION
RENAL ARTERY IRRADIATION FOR SYMPATHETIC RENAL DENERVATION IN PATIENTS WITH RESISTANT HYPERTENSION
Enrollment Status: Terminated
Publish Date: January 13, 2022
Intervention Type: Radiation
Study Phase: Not Applicable
Strategies to Prevent Transcatheter Heart Valve Dysfunction in Low Risk Transcatheter Aortic Valve Replacement
Strategies to Prevent Transcatheter Heart Valve Dysfunction in Low Risk Transcatheter Aortic Valve Replacement
Enrollment Status: Unknown
Publish Date: January 04, 2022
Intervention Type: Other, Device
Study Phase: Not Applicable
REPRISE III: Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus™ Valve System - Randomized Clinical Evaluation
REPRISE III: Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus™ Valve System - Randomized Clinical Evaluation
Enrollment Status: Terminated
Publish Date: December 17, 2021
Intervention Type: Device
Study Phase: Not Applicable
Atherosclerotic Coronary Vulnerable Plaque: Correlation With Coronary Artery Calcium
Atherosclerotic Coronary Vulnerable Plaque: Correlation With Coronary Artery Calcium
Enrollment Status: Withdrawn
Publish Date: July 02, 2021
Intervention Type: Other
Study Phase: Not Applicable
A Randomized Evaluation of the TriGuard Embolic Deflection Device to Reduce the Impact of Cerebral Embolic Lesions After Transcatheter Aortic Valve Implantation
A Randomized Evaluation of the TriGuard Embolic Deflection Device to Reduce the Impact of Cerebral Embolic Lesions After Transcatheter Aortic Valve Implantation
Enrollment Status: Completed
Publish Date: February 18, 2021
Intervention Type: Procedure, Device
Study Phase: Not Applicable
The Safety and Efficacy of an Extravascular, Water-Soluble Sealant for Venous Access-Site Closure
The Safety and Efficacy of an Extravascular, Water-Soluble Sealant for Venous Access-Site Closure
Enrollment Status: Completed
Publish Date: November 18, 2020
Intervention Type: Device, Other
Study Phase: Phase 4
Pivotal Clinical Study to EvaluAte the SaFety and Effectiveness of MANTA Vascular Closure Device
Pivotal Clinical Study to EvaluAte the SaFety and Effectiveness of MANTA Vascular Closure Device
Enrollment Status: Completed
Publish Date: September 25, 2019
Intervention Type: Device
Study Phase: Not Applicable
View 25 Less Clinical Trials

935 Total Publications

Reply to "Bleeding events of cangrelor usage for the treatment of patients with acute coronary syndrome: Gender differences or study design Bias?"
Reply to "Bleeding events of cangrelor usage for the treatment of patients with acute coronary syndrome: Gender differences or study design Bias?"
Journal: International journal of cardiology
Published: October 02, 2025
Similar Doctors
Distinguished in Hypertrophic Cardiomyopathy (HCM)
Dr. Jose A. Madrazo
Cardiology
Distinguished in Hypertrophic Cardiomyopathy (HCM)
Dr. Jose A. Madrazo
Cardiology

Johns Hopkins University

600 N Wolf St, 
Baltimore, MD 
 (34.1 miles away)
410-955-5000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Jose Madrazo is a Cardiologist in Baltimore, Maryland. Dr. Madrazo is rated as a Distinguished provider by MediFind in the treatment of Hypertrophic Cardiomyopathy (HCM). His top areas of expertise are Hypertrophic Cardiomyopathy (HCM), Cardiomyopathy, Familial Hypertrophic Cardiomyopathy, and Heart Attack. Dr. Madrazo is currently accepting new patients.

Edward K. Kasper
Distinguished in Hypertrophic Cardiomyopathy (HCM)
Dr. Edward K. Kasper
Advanced Heart Failure and Transplant Cardiology | Cardiology
Distinguished in Hypertrophic Cardiomyopathy (HCM)
Dr. Edward K. Kasper
Advanced Heart Failure and Transplant Cardiology | Cardiology

Johns Hopkins University

601 N Caroline St, 
Baltimore, MD 
 (33.9 miles away)
410-955-5080
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Edward Kasper is an Advanced Heart Failure and Transplant Cardiologist and a Cardiologist in Baltimore, Maryland. Dr. Kasper is rated as a Distinguished provider by MediFind in the treatment of Hypertrophic Cardiomyopathy (HCM). His top areas of expertise are Cardiomyopathy, Familial Hypertrophic Cardiomyopathy, Sengers Syndrome, Hypertrophic Cardiomyopathy (HCM), and Heart Transplant. Dr. Kasper is currently accepting new patients.

Bradley A. Maron
Distinguished in Hypertrophic Cardiomyopathy (HCM)
Dr. Bradley A. Maron
Cardiology
Distinguished in Hypertrophic Cardiomyopathy (HCM)
Dr. Bradley A. Maron
Cardiology

University Of Maryland Physicians PA

22 S Green St, 
Baltimore, MD 
 (32.4 miles away)
410-328-8040
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Bradley Maron is a Cardiologist in Baltimore, Maryland. Dr. Maron is rated as a Distinguished provider by MediFind in the treatment of Hypertrophic Cardiomyopathy (HCM). His top areas of expertise are Pulmonary Hypertension, Hypertension, Heart Failure, Hypertrophic Cardiomyopathy (HCM), and Heart Transplant. Dr. Maron is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Waksman's expertise for a condition
ConditionClose
View All 9 Elite Conditions
View All 11 Distinguished Conditions
View All 13 Advanced Conditions
View All 25 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile